Schering acquires Japanese rights to MS-325

Article

An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral

An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral vascular disease with MRI.

Schering gained worldwide sales and marketing rights to the product, excluding Japan, in June. The terms of the latest deal call for Schering to pay Epix $3 million up front, along with additional milestone payments. Simultaneously with this transaction, Epix reacquired rights to the Japanese market for MS-325 from Daiichi Radioisotope Laboratories. Under terms of that agreement, Epix will pay Daiichi $2.8 million in up-front fees and additional milestone payments. Daiichi will also receive a royalty from Epix on net sales of MS-325 in Japan.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.